Capital Rx
Capital Rx continues to champion access to cost-effective biosimilar solutions for Humira® (adalimumab) while mitigating financial risks and disruption for members and plan sponsors. Beginning in 2025, Capital Rx’s formularies will include several low-WAC, high-concentration biosimilars manufactured and commercialized by Organon/Samsung Bioepis (Hadlima®), Teva/Alvotech (Simlandi®), Sandoz (adalimumab-adaz), and Celltrion (adalimumab-aaty).
Given the rapidly evolving market and the potential benefits of promoting biosimilar adoption, adding these biosimilars from established manufacturers with strong pipelines improves patient access to affordable therapeutic options.
Today, these biosimilars yield relatively low net costs for a 30-day supply, and the benefits of adding them alongside Humira include flexibility for patients, prescribers, and plan sponsors. “Since Capital Rx is agnostic, does not own dispensing assets, and passes through 100% of rebates, clients are free to optimize their plan designs and be nimble if circumstances change,” said Sara Izadi, PharmD, Capital Rx’s Chief Clinical Officer. “The net cost difference between Humira and these biosimilar agents is very close. Our goal is to provide safe and effective alternatives and ensure appropriate access so plan sponsors can address unique population needs.”
With the addition of these products to formularies, clients can choose between retaining Humira in a parity position to biosimilars or leveraging a biosimilars-first strategy without concern about misaligned incentives. Additionally, JUDI® provides the infrastructure needed to support any plan design decision to optimize the formulary strategy they choose.
“Helping our clients understand how to optimize plan designs to ensure member and plan savings with each choice and providing full visibility into the supply chain economics leads to appropriate decision-making, which is always our priority,” added Sara.
Related Content
To learn more about Capital Rx’s formulary options, please visit: www.cap-rx.com/prescribers#prescriber-forms.
To learn more about Capital Rx’s full-service pharmacy benefit management solutions or clinical programs, please contact our team.